Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (HOOK) has described itself as a clinical-stage biopharmaceutical company developing next generation immunotherapeutics based on a proprietary arenavirus platform. Its news flow has highlighted programs in oncology and serious infectious diseases, including product candidates targeting HPV16-positive cancers, KRAS mutated cancers, and viral infections such as hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Company press releases provide detailed updates on its collaboration and license agreement with Gilead Sciences, Inc. For example, HOOKIPA has reported on the HB-400 program in clinical development for HBV and the HB-500 program, a next-generation therapeutic vaccine being evaluated as a potential component of a curative regimen for HIV. News items have described clinical milestones such as enrollment completion in a Phase 1b trial of HB-500, including trial design elements and the intended role of HB-500 in a combination strategy for a potential functional cure of HIV.
HOOKIPA’s news coverage has also included significant corporate and strategic developments. In early 2025, the company issued multiple announcements related to a potential all-share combination with Poolbeg Pharma plc and associated U.K. Takeover Code disclosure requirements, followed by a Rule 2.8 statement that it did not intend to make an offer under Rule 2.7 of the Code. Subsequent releases detailed an asset purchase agreement with Gilead for HOOKIPA’s HB-400 program assets and certain HB-500 assets, and explained how this transaction related to the company’s long-term prospects and strategies.
Later announcements document HOOKIPA’s intention to voluntarily delist its common stock from the Nasdaq Capital Market, deregister its common stock under the Securities Exchange Act of 1934, and seek stockholder approval for dissolution and liquidation. Investors using this news page can review the sequence of clinical updates, collaboration news, U.K. takeover-related disclosures, and corporate actions such as the asset sale to Gilead, the special meeting of stockholders, and the steps toward delisting and deregistration. This provides a consolidated view of both scientific progress and material corporate events affecting HOOKIPA and the HOOK symbol.
HOOKIPA (OTCID: HOOK) completed the sale of its HB-400 assets and certain HB-500 assets to Gilead. HOOKIPA entered into an Asset Purchase Agreement with Gilead on May 21, 2025, and the transaction closed on October 30, 2025. The assets sold relate to HOOKIPA’s HB-400 program in clinical development for hepatitis B virus and certain assets of the HB-500 program in clinical development for HIV.
HOOKIPA noted the programs were developed in collaboration with Gilead under an existing collaboration and license agreement. The company directs investors to its investor relations website, OTC Markets filings, press releases, conference calls, webcasts, and social media for additional material information.
HOOKIPA Pharma (NASDAQ: HOOK) has announced its intention to voluntarily delist from the Nasdaq Capital Market and deregister its common stock. This decision follows a significant asset purchase agreement with Gilead Sciences signed on May 21, 2025, where Gilead will acquire HOOKIPA's HB-400 program (for hepatitis B treatment) and certain assets of the HB-500 program (for HIV treatment).
The company will hold a special stockholder meeting on July 29, 2025, to approve both the asset sale and the company's dissolution. If approved, HOOKIPA plans to file for dissolution with Delaware and expects its delisting to become effective around August 8, 2025. The company cited ongoing reporting requirements as economically burdensome and potentially reducing assets available for stockholder distribution.
HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025.
The company retains the right to revisit this decision under specific circumstances, including: with Poolbeg's board agreement, following a third-party offer for Poolbeg, after a Rule 9 waiver or reverse takeover announcement by Poolbeg, or if the Panel on Takeovers and Mergers determines a material change in circumstances.
Moelis & Company is acting as financial adviser to HOOKIPA in this matter.
HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025.
The company reserves the right to revisit this decision under specific circumstances, including: agreement from Poolbeg's board, announcement of a third-party offer for Poolbeg, announcement of a Rule 9 waiver or reverse takeover by Poolbeg, or if the Panel on Takeovers and Mergers determines a material change in circumstances.
Moelis & Company is acting as financial adviser to HOOKIPA in this matter. The announcement will be available on HOOKIPA's website by noon the following business day.
HOOKIPA Pharma (NASDAQ: HOOK) has completed enrollment for its Phase 1b clinical trial of HB-500, a next-generation therapeutic HIV vaccine developed in collaboration with Gilead Sciences. The trial, which enrolled 30 participants across five U.S. sites, began on July 1, 2024, with primary completion expected in H2 2025.
The Phase 1b trial (NCT06430905) aims to evaluate safety, tolerability, reactogenicity, and immunogenicity of repeated HB-500 doses in HIV patients on suppressive antiretroviral treatment. The study design includes two dose escalation cohorts with participants randomized to receive either HB-500 or placebo.
HB-500 is designed to induce robust and durable immunity as part of a combination strategy for potential functional HIV cure. Under the collaboration agreement, HOOKIPA will advance the program through Phase 1b completion, after which Gilead has exclusive rights to assume further development.
Poolbeg Pharma and HOOKIPA Pharma have provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer is made
2. Participate in the proposed Fundraise for up to $8.7495 million, in line with its existing contractual obligations
The companies emphasize that all discussions regarding the potential combination remain non-binding and non-exclusive, with no guarantee that a firm offer will be made or that any transaction will be completed.
HOOKIPA Pharma Inc (HOOK) has filed a Form 8 Public Opening Position Disclosure on January 8, 2025, related to takeover code regulations. The disclosure reveals detailed information about stock positions and options held by company directors and executives. Key directors Julie O'Neill and David R. Kaufman each hold less than 500 common shares. The company has granted various stock options to directors under its 2019 Stock Option and Incentive Plan, with exercise prices ranging from $6.44 to $166.10 and different vesting schedules. Notable grants include 108,695 restricted stock units to Malte Peters and 69,875 to Terry Coelho, both vesting in two equal installments on July 22, 2025 and 2026.
HOOKIPA Pharma (NASDAQ: HOOK) has issued a notice to shareholders regarding U.K. disclosure requirements related to its potential all-share acquisition of Poolbeg Pharma plc, which was announced on January 2, 2025. The notice specifically addresses Rule 8 of the UK City Code on Takeovers and Mergers.
Under Rule 8.3, shareholders with interests of 1% or more in any class of relevant security must make both an Opening Position Disclosure and a Dealing Disclosure if they trade in any relevant security during the offer period. The company's common stock, Class A common stock, and Series A, A-1, and A-2 convertible preferred stock are considered relevant securities for this offer period.
Poolbeg Pharma and HOOKIPA Pharma have announced important updates regarding their potential combination. Gilead Sciences, a significant HOOKIPA shareholder owning 19.4% (1,875,947 shares) of HOOKIPA's issued share capital, has indicated its intention to vote in line with HOOKIPA Board's recommendation for a formal offer and participate in the proposed fundraise.
HOOKIPA has revised its fundraising plans, now expecting to undertake a 100% primary private placement of approximately $30 million+, an increase from the previously announced 'up to $30 million'. Oppenheimer & Co. Inc. has been engaged as the placement agent for this private placement fundraise.
The companies emphasize that all discussions about the potential combination remain non-binding and non-exclusive, with no guarantee that a firm offer will be made or any transaction completed.
HOOKIPA Pharma has issued an amendment to its Rule 2.4 announcement from January 2, 2025, regarding a potential combination with Poolbeg Pharma plc. The amendment corrects the ISIN of HOOKIPA's common stock from US43906K1007 to US43906K2096, which became effective after the company's 1-for-10 reverse stock split on July 9, 2024.
The company confirms having 9,655,022 shares of common stock, 2,399,517 shares of Class A common stock, 370 shares of Series A convertible preferred stock, 10,800 shares of Series A-1 convertible preferred stock, and 15,268 shares of Series A-2 convertible preferred stock outstanding. Class A common stock holders can convert ten shares into one common stock share, while Series A, A-1, and A-2 preferred stock can be converted into 100 common shares each, subject to ownership limitations.
FAQ
What is the current stock price of Hookipa Pharma (HOOK)?
What is the market cap of Hookipa Pharma (HOOK)?
